Do you want to read an article? Please log in or register.
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Tuberculosis
RECOMMENDED
Related content
RECOMMENDED
Tuberculosis
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reiman M, Crudu V, Botnaru V, Lange C
doi: 10.1183/13993003.02544-2020
RECOMMENDED
Tuberculosis
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017.
doi: 10.1016/S2213-2600(20)30047-3.
RECOMMENDED
Tuberculosis
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM
doi: 10.1016/S0140-6736(20)31316-7.
RECOMMENDED
Tuberculosis
Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
N Engl J Med.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills G, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M
doi: 10.1056/NEJMoa1901814.
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Am J Respir Crit Care Med.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C
doi: 10.1164/rccm.
CoughTuberculosis
Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.
Lancet Respir Med.
Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T1, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM
doi: 10.1016/
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Lancet Respir Med.
Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D
doi: 10.1016/S2213-2600
RECOMMENDED
Tuberculosis
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Lancet Respir Med.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R
doi: 10.1016/S2213-2600(18)30426-0.
Tuberculosis
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med.
Lessem E, Cox V, Furin J